CRESTBRIDGE
14.12.2020 15:32:17 CET | Business Wire | Press release
Crestbridge, the agile alternative for private equity and real estate administration solutions, has announced that it intends to acquire New Jersey based Ovation Fund Services. Ovation is a provider of fund administration, accounting and reporting services to US domestic private equity and real estate funds. The acquisition complements Crestbridge’s core service offering in both asset classes.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201214005445/en/
Ovation will become part of the Crestbridge brand from 31 December 2020 and is the business’ seventh office. All Ovation employees will become members of the global Crestbridge team, ensuring continuity of client service and working with the wider Crestbridge Group to continue to grow and develop the current services offering.
The acquisition substantially expands Crestbridge’s presence in the US, where it already has an office in New York, and its ability to service private equity and real estate funds. It also enhances the multi-jurisdiction proposition to its client base as the new office complements Crestbridge’s existing network of offices in London, Luxembourg, Bahrain, the Cayman Islands, New York and Jersey (Channel Islands), providing access to its international team of experts for North American clients.
Commenting on the new office, Paul Perris, Chief Commercial Officer of the Crestbridge Group said: “This is another significant achievement in delivering our global expansion strategy and widening access to our solutions for private equity and real estate fund managers. In particular, this provides North American based clients access to European investment markets and turnkey solutions, which continues to be an increasingly strong trend, as well as supporting inward investment into North America. We are very much looking forward to supporting our global client base and helping facilitate their continued success.”
The New Jersey office will be headed by Scot Hadley, Ovation’s founder, who has over 23 years’ experience growing businesses and building long-term relationships within the private equity and real estate industry in the US and beyond. Scot established Ovation nearly four years ago, building a successful business with a loyal customer base. Prior to establishing Ovation, Scot spent 18 years of his career at Paladin Realty Partners, an institutional real estate fund manager, where he was one of ten founding members of the firm.
Scot commented: “We believe that bringing the quality and breadth of Crestbridge’s global capabilities together with our focus on the US markets is very attractive to current and prospective clients. Access to a global team with the same high standards as ours will be a huge benefit and we’re excited by the opportunities.”
The office is based in Morristown, New Jersey. The financial terms of the acquisition are not being disclosed.
This latest acquisition in North America also follows the announcement of ‘Crestbridge Fiduciary LLC’, created to better support families with US-based interests. This joint venture with Wyoming-based Willow Street was formed in response to exceptional client demand for Family Office Services and consolidates Crestbridge’s global expertise with Willow Street’s in-depth trust and fiduciary capability and high-calibre client base.
Ends.
Notes to editors
- We are a leading global administration, management & corporate governance solutions business.
- We provide a broad range of outsourced fiduciary, administrative, accounting and compliance services globally – our expertise spans services, asset classes and jurisdictions. Since 1998, we have been putting our insight and experience to work for clients who include leading corporations, sovereign wealth funds, investor groups, asset managers and ultra-high net worth families.
- Crestbridge employs over 350 people and has six international offices: Bahrain, Cayman Jersey, London, Luxembourg and New York.
- For our regulatory information please see here for more details.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201214005445/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting tilføjer House of Code for at styrke teknologi- og dataløsninger26.6.2026 20:01:00 CEST | Pressemeddelelse
Andersen Consulting forstærker sine kompetencer inden for teknologisk transformation gennem en samarbejdsaftale med House of Code, en global virksomhed med hovedkvarter i USA, der specialiserer sig i datadrevne platforme, automatisering og agentbaserede ai-løsninger. House of Code blev stiftet i 2001 og udvikler softwareløsninger samt yder rådgivning til energihandels- og finanssektoren med kunder, der spænder over hedgefonde, kapitalfonde og forsyningsvirksomheder. Virksomheden besidder dyb ekspertise inden for energihandel og risikostyring og hjælper organisationer med systemimplementering, forretningstransformation, dataautomatisering og ai-underbygget modernisering af arbejdsgange. Deres proprietære platform, Enterprise Platform for Integrated Compliance (EPIC), skaber en mere effektiv datastyring, automatiserer rapporteringsprocesser, forbedrer den driftsmæssige gennemsigtighed på tværs af virksomhedssystemer og skaber et fundament for opbygning af intelligente, agentbaserede arbe
Capco Recognized by OpenAI for Innovation and Responsible AI Leadership26.6.2026 20:00:00 CEST | Press release
Receives AI Governance & Risk Excellence Award at OpenAI Partner SummitCapco’s UK AI Lab wins OpenAI Codex Hackathon Global management and technology consultancy Capco, a Wipro company,has been recognized by OpenAI for both AI innovation and responsible AI leadership. Capco received the AI Governance & Risk Excellence Award at the recent OpenAI Partner Summit 2026 in San Francisco, highlighting Capco’s ability to deliver enterprise-grade AI outcomes in highly regulated environments. The award recognizes Capco’s expert advantage when helping financial services and energy organizations to scale AI with confidence, balancing innovation with strong governance to reduce risk, strengthen compliance and improve customer outcomes. This award follows Capco winning the OpenAI Codex Hackathon, where its UK AI Lab competed against more than 30 teams and over 100 participants from across the OpenAI partner ecosystem. Capco's winning entry Sentra – a consulting-led, AI-powered retail banking solutio
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
